drugset / Trial / NCT01757275

High Dose Esomeprazole Na for Prevention of Rebleeding After Successful Endoscopic Therapy of a Bleeding Peptic Ulcer

NCT01757275

Phase 3 Completed 239 enrolled AstraZeneca
RandomizedParallel-groupQuadruple-blindPrevention

Summary

To describe the rate of clinically significant rebleeding during 72 hours continuous i.v. infusion of high dose esomeprazole Na in patients in China with primary successful endoscopic haemostatic therapy of a bleeding peptic ulcer, with cimetidine i.v. in

Timeline

Start
2013-02
Primary completion
2014-12
Completion
2014-12

Drugs

EvaluationDrugModalityDoseRoute
Comparator Cimetidine Small molecule 60 mg Intravenous
Subject Esomeprazole Small molecule 8 mg Intravenous
Subject Esomeprazole Small molecule 40 mg Intravenous